Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor
Portfolio Pulse from
Eli Lilly's Jaypirca (pirtobrutinib) has received a positive recommendation from the CHMP for approval in the EU for treating relapsed or refractory chronic lymphocytic leukemia (CLL) in adults previously treated with a BTK inhibitor. This decision is based on the Phase 3 BRUIN CLL-321 trial results.
February 28, 2025 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Jaypirca has been recommended for approval by the CHMP for treating CLL in the EU, based on positive Phase 3 trial results. This could enhance Eli Lilly's market position in the oncology sector.
The CHMP's positive recommendation for Jaypirca is a significant regulatory milestone for Eli Lilly, potentially leading to increased sales in the EU market. The positive Phase 3 trial results further support the drug's efficacy, likely boosting investor confidence and positively impacting LLY's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100